Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Binge eating disorder (full criteria as described in the American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 5th edition);~* BMI in the obesity (BMI \>30 and \<50) or non-obesity (BMI \>21.5 and \<29.9) range;~* Available for the duration of the treatment and follow-up (15 months);~* Read, comprehend, and write English at a sufficient level to complete study-related materials.~Exclusion Criteria:~* Currently taking opioid pain medications or drugs; or positive drug screen for opiates~* Currently taking medications that influence eating/weight;~* History of seizures;~* Current substance use disorder or other severe psychiatric disturbance (e.g., suicidality);~* Past or current anorexia nervosa or bulimia nervosa;~* Pregnant or breastfeeding;~* Medical status judged by study physician as contraindication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- NB Medication (Type: EXPERIMENTAL): Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be inactive and taken daily in pill form.

Based on this trial design, predict the completion outcome and termination type (if applicable).